Andipal (Andipal)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBendazole + Metamizol sodium + Papaverine + PhenobarbitalBendazole + Metamizol sodium + Papaverine + Phenobarbital
Similar drugsTo uncover
  • Andipal
    pills inwards 
    UZOLE-SIBERIAN CHEMICAL PLANT, OJSC     Russia
  • Andipal
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Andipal
    pills inwards 
    PHARMSTANDART-TOMSKHIMFARM, OJSC     Russia
  • Andipal
    pills inwards 
    Barnaul Plant of Medical Preparations, LLC     Russia
  • Andipal
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Andipal
    pills inwards 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
  • Andipal
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Andipal
    pills inwards 
    UZOLE-SIBERIAN CHEMICAL PLANT, OJSC     Russia
  • Andipal Avexima
    pills inwards 
    ASFARMA, LLC     Russia
    • Dosage form: & nbsppills
    Composition:

    1 tablet contains:

    Active substances:

    Bendazole hydrochloride (dibasol) 0.02 g

    Metamizole sodium monohydrate (analgin) - 0.25 g

    Papaverine hydrochloride - 0.02 g

    Phenobarbital - 0.02 g

    Excipients:

    potato starch - 0.0489 g, talc 0.0074 g, stearic acid 0.0037 g.

    Description:

    Tablets white or white with a slightly yellowish hue of color, flat-cylindrical shape with a facet and a risk.

    Pharmacotherapeutic group:Metamizole sodium, in combination with psychotropic drugs
    ATX: & nbsp

    N.02.B.B.52   Metamizole sodium in combination with other drugs, excluding psycholeptics

    Pharmacodynamics:

    Combined drug, has a vasodilating, analgesic, spasmolytic and sedative effect.

    Andipal, as an antispasmodic, is used for spasms of peripheral vessels and vessels of the brain.

    Reducing the overall peripheral resistance, acting on arterioles, the drug lowers blood pressure, improves collateral circulation. Combination of myotropic type spasmolytics (benzazole and papaverine) with metamizole sodium increases the analgesic effect of the latter with headache, migraine. The presence of phenobarbital in the preparation promotes the manifestation of a sedative effect and the enhancement of the action of other components.

    Pharmacokinetics:

    Metamizol sodium: Good and quickly absorbed in the gastrointestinal tract. In the intestinal wall it hydrolyzes with the formation of an active metabolite, unchanged metamizol sodium in the blood is absent (only after intravenous administration, its insignificant concentration is detected in the plasma). The association of the active metabolite with proteins is 50-60%. Metabolized in the liver, excreted by the kidneys.In therapeutic doses penetrates into the mother's milk.

    Papaverine: Absorption depends on the dosage form. Bioavailability on average - 54%. The connection with plasma proteins is 90%. Well distributed, penetrates through the histohematological barriers. Metabolised in the liver. T1 / 2 - 0.5-2 hours (can 2 4 9 7 3 extend to 24 hours). It is excreted by the kidneys in the form of metabolites. Completely removed from the blood during hemodialysis.

    Phenobarbital: When administered orally phenobarbital completely, but relatively slowly absorbed. The maximum concentration in the blood is observed 1-2 hours after administration. About 50% is bound by plasma proteins. The drug is evenly distributed in different organs and tissues; smaller concentrations of it are found in the brain tissues. The half-life in adults is 2 to 4 days. Isolated from the body slowly, which creates the prerequisites for cumulation. Metabolized by microsomal enzymes of the liver. It is excreted by the kidneys in the form of inactive metabolites, 25-50% - unchanged.

    Indications:

    Pain syndrome associated with spasm of peripheral arteries, smooth muscles of the gastrointestinal tract, cerebral vessels; arterial hypertension.

    Contraindications:

    Hypersensitivity, hepatic insufficiency, chronic renal failure, glucose-6-phosphate dehydrogenase deficiency, blood diseases, tachyarrhythmia, severe angina, decompensated chronic heart failure, angle-closure glaucoma, prostatic hyperplasia, intestinal obstruction, megacolon, pregnancy, lactation period, 8 years, bronchial asthma, triggered by the use of acetylsalicylic acid, salicylates and other non-steroidal anti-inflammatory drugs arats.

    Dosing and Administration:

    Inside.

    1-2 tablets 2-3 times a day. The course of treatment is 7-10 days.

    Side effects:Drowsiness, decreased speed of psychomotor reactions, lowering of blood pressure, impaired liver / kidney function. Sometimes there is nausea, constipation, allergic reactions (up to anaphylactic shock). With prolonged use of the drug, it is possible to depress the blood because of the presence of metamizole sodium (leukopenia, rarely agranulocytosis, thrombocytopenia). The presence of phenobarbital may have a sedative effect, sometimes the occurrence of ataxia, depression (especially in elderly and weakened patients) is possible.
    Overdose:

    In case of an overdose, there is severe drowsiness, dizziness, a collapsoid condition.

    First aid: washing the stomach, taking activated charcoal. Symptomatic therapy.

    Interaction:

    Pharmacodynamic: combination with nitrates (including nitroglycerine, isosorbide dinitrate), slow calcium channel blockers (including nifedipine), amiodarone, beta-blockers (including propranolol, metopropol, oxprenolol, talinolol), ganglioblocators (including azamethonium bromide), diuretics (including furosemide, hydrochlorothiazide), myotropic antispasmodics (including dipyridamole, aminophylline) increases the hypotensive effect of Andipal.

    Joint application of alpha-adrenomimetics direct (including epinephrine, norepinephrine) and indirect (ephedrine) type of action, H-cholinomimetics (including nicotine, acetylcholine), analeptics (including camphor, sulphocamphocaine [procaine + sulfocamphoric acid], nikethamide, bemegrid, lobelia, cytisine), tonic (including ginseng root, eleutherococcus prickly rhizomes and roots extract, rhodiola extract) and Andipal reduces the hypotensive effect of the latter.

    Mutual increase in the risk of side effects when used simultaneously with narcotic analgesics.

    Pharmacokinetic: combination of adsorbents (Activated carbon), astringent and enveloping agents reduces the absorption of the drug in the gastrointestinal tract.

    Special instructions:

    At long (more than 7 days) application control of a picture of peripheric blood and a functional status of a liver is necessary.

    Effect on the ability to drive transp. cf. and fur:During the treatment period, it is necessary to refrain from engaging in potentially dangerous activities that require a high concentration of attention and speed of psychomotor reactions.
    Form release / dosage:

    Pills.

    Packaging:

    10 tablets per contour cell packaging made of polyvinylchloride film and foil of aluminum printed lacquered or paper packaging with polymer coating.

    For 10 tablets in a contour non-cellular package of paper with a polymer coating.

    By 10,20, 30,40, 50, 60,100 tablets in a can of polymer.

    Each jar or 1, 2, 3, 4, 5 contour mesh packages together with the instructions for use are placed in a bundle.

    Banks polymer or contour packs with an equal number of instructions for use are placed in a group package.

    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years 6 months Do not use after the expiry date shown on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-007455/10
    Date of registration:30.07.2010 / 17.12.2012
    Expiration Date:Unlimited
    The owner of the registration certificate:URALBIOFARM, OJSC URALBIOFARM, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp05.09.2017
    Illustrated instructions
      Instructions
      Up